388,000 Shares in Inhibrx, Inc. (NASDAQ:INBX) Acquired by Slotnik Capital LLC

Slotnik Capital LLC acquired a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 388,000 shares of the company’s stock, valued at approximately $5,975,000. Inhibrx comprises about 2.7% of Slotnik Capital LLC’s holdings, making the stock its 12th biggest position.

Other large investors have also made changes to their positions in the company. HighTower Advisors LLC acquired a new position in shares of Inhibrx in the fourth quarter worth about $12,039,000. Geode Capital Management LLC bought a new position in Inhibrx during the 4th quarter worth $3,930,000. Bank of New York Mellon Corp acquired a new position in Inhibrx during the 4th quarter valued at about $792,000. Charles Schwab Investment Management Inc. acquired a new stake in Inhibrx in the 4th quarter valued at approximately $503,000. Finally, Meridian Wealth Advisors LLC bought a new position in shares of Inhibrx in the fourth quarter valued at approximately $385,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Inhibrx Stock Up 0.4 %

Shares of NASDAQ:INBX opened at $14.10 on Thursday. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $35.42. The stock’s 50-day moving average is $13.38 and its 200-day moving average is $14.57.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Analysts Set New Price Targets

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.